Search research articles
Contact Us
Filters
Showing results (231-240 of 248) with videos related to
Page
of 25
Sort By:
International Journal of Cancer
|
July 7, 2018
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Yeon Hee Park, Kyung-Hun Lee, Joo Hyuk Sohn, et al.
Cancer Research and Treatment
|
October 15, 2016
Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
Seongyeong Kim, Ahrum Min, Kyung-Hun Lee, et al.
Cytokine
|
March 26, 2021
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)
Ju Won Kim, Soohyeon Lee, Hye Sook Kim, et al.
The Lancet. Oncology
|
November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
Nature Communications
|
August 11, 2021
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
Deukchae Na, Jeesoo Chae, Sung-Yup Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2025
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer
Seung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
Kyung-Hun Lee, Hye Jung Chang, Sae-Won Han, et al.
The Lancet. Oncology
|
February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Hee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
BMC Medicine
|
March 17, 2022
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Breast Cancer Research and Treatment
|
May 18, 2020
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial
Han-Byoel Lee, Wonshik Han, Soo-Yeon Kim, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 248) with videos related to
Sort By:
Page
of 25
International Journal of Cancer
|
July 7, 2018
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
Yeon Hee Park, Kyung-Hun Lee, Joo Hyuk Sohn, et al.
Cancer Research and Treatment
|
October 15, 2016
Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
Seongyeong Kim, Ahrum Min, Kyung-Hun Lee, et al.
Cytokine
|
March 26, 2021
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)
Ju Won Kim, Soohyeon Lee, Hye Sook Kim, et al.
The Lancet. Oncology
|
November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
Nature Communications
|
August 11, 2021
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
Deukchae Na, Jeesoo Chae, Sung-Yup Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 20, 2025
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer
Seung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
Kyung-Hun Lee, Hye Jung Chang, Sae-Won Han, et al.
The Lancet. Oncology
|
February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Hee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
BMC Medicine
|
March 17, 2022
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
Ryan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Breast Cancer Research and Treatment
|
May 18, 2020
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial
Han-Byoel Lee, Wonshik Han, Soo-Yeon Kim, et al.
Page
of 25